Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma

INTRODUCTION: The combination of ipilimumab plus nivolumab has been used as first‐line therapy for metastatic renal cell carcinoma. While it is well known that hemodialysis patients have a higher rate of renal cell carcinoma compared to the general population, no reports have described the safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwaki, Takuya, Niimi, Aya, Kano, Masato, Kurokawa, Yoshiaki, Yoshizaki, Uran, Nozaki, Keina, Nomiya, Akira, Miyazaki, Hideyo, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784770/
https://www.ncbi.nlm.nih.gov/pubmed/33426493
http://dx.doi.org/10.1002/iju5.12231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784770/
https://www.ncbi.nlm.nih.gov/pubmed/33426493
http://dx.doi.org/10.1002/iju5.12231

Ejemplares similares